Complex therapy of non-alcoholic fatty liver disease in combination with the syndrome of intestinal bacterial overgrowth

Journal Title: Сучасна гастроентерологія - Year 2019, Vol 0, Issue 1

Abstract

Objective — to study the effects of three-month administration of the combined cytoprotector L-Betargin on the lipid and carbohydrate metabolism, biochemical markers of liver damage, the degree of its steatosis and fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) against the background of metabolic syndrome (MS), depending on the presence of syndrome of intestinal bacterial overgrowth (SIBO) and after its correction with probiotic Spazmolac. Materials and methods. Observations involved 60 patients with NASH, developing against the MS background. The diagnosis of steatohepatitis was established based on the multimodal sonographic study of the liver, including conventional echography, Doppler sonography, shear wave elastography, and liver steatometry. The degree of steatosis (S1-S3) was determined by the attenuation coefficient (CG) of the ultrasonic wave SAR, the degree of fibrosis (F1-F4) by the average hardness of the parenchyma. The MS presence was confirmed with generally accepted diagnostic criteria. The SIBO diagnosis was established using the H2-lactulose hydrogen test. All patients were evaluated abdominal symptoms — dyspepsia, pain, bloating, stool frequency. The biochemistry included determination of the transaminases, gamma-glutamine transferase, the levels of bilirubin and fractions, HbA1c, cholesterol, low and high-density lipoproteins, triglycerides. The patients were randomized into two comparable groups. The first group consisted of 30 subjects, who were administered L-Betargin for 3 months in a dose of 1 stick 3 times a day, 30 patients of second group people took silymarin 45 mg 3 times a day. Four weeks after the treatment start, the SIBR, biochemical parameters and multimodal liver sonography were monitored with an assessment of the steatosis and fibrosis degree. In case of SIBR presence, the probiotic Spazmolac, 1 capsule per day for 4 weeks, was added to the treatment. In 12 weeks after the treatment start, clinical, biochemical, sonographic indicators and SIBR were re-evaluated. Results. The use of L-Betargin in NAFLD for 12 weeks in a dose of 1 stick 3 times a day resulted in the significant suppression of cytolysis, a decrease in liver steatosis, an improvement in lipid metabolism and portal blood flow rates, and also reduction of the risk of developing or progression of atherosclerosis, cardiovascular diseases and insulin resistance. Conclusions. Due to its combined composition, synergy of mechanisms of action and normalization of metabolic disorders, L-Betargin contributes to the elimination of asthenic syndrome in patients with NAFLD and improves their quality of life. The four-week administration of the probiotic Spazmolac promoted almost two-fold SIBO reduction, that was accompanied by a significant decrease in the severity of abdominal pain, bloating and diarrhea. The use of L-Betargin resulted in the increased efficacy of SIBR eradication.

Authors and Affiliations

A. E. Dorofeyev, M. M. Rudenko, S. M. Tkach, Yu. Z. Dynia

Keywords

Related Articles

Pancreatogenic diabetes vice versa: exocrine pancreatic insufficiency against the background of diabetes mellitus

The analysis has been performed for the normal physiological interrelations of exocrine and endocrine pancreatic parenchyma. There were elucidated literature data regarding pathogenesis, clinical peculiarities, treatment...

The gastroenterological manifestations of methotrexate effects in pediatric patients with the juvenile idiopathic arthritis

The paper elucidates the most prevalent gastroenterological manifestations of methotrexate effects in the treatment of juvenile idiopathic arthritis (JIA) in pediatric patients. Some considerable changes took place in th...

The features of vegetative and emotional disorders at chronization of duodenal ulcer

Traditionally, duodenal ulcer is referred to the psychosomatic disorders. Not by accident, in the classic investigations of the founder of the stress theory, Canadian scientist R. Selye, acute gastric ulcer serves as a m...

Age-related and hormonal and metabolic peculiarities of patients with non-alcoholic fatty liver disease in combination with subclinical hypothyroidism

Objective — to identify age-related and hormonal and metabolic features in patients with non-alcoholic fatty liver disease (NAFLD) in combination with subclinical hypothyroidism (SH). Materials and methods. The study in...

Peculiarities of the clinical course and visceral adipose tissue in patients with non-alcoholic fatty liver disease against the background of metabolic syndrome

Objective — to study the peculiarities of metabolic disturbances in patients with nonalcoholic fatty liver disease (NAFLD) and their role in the development and progression of liver steatosis. Materials and methods. Inv...

Download PDF file
  • EP ID EP508547
  • DOI 10.30978/MG-2019-1-77
  • Views 270
  • Downloads 0

How To Cite

A. E. Dorofeyev, M. M. Rudenko, S. M. Tkach, Yu. Z. Dynia (2019). Complex therapy of non-alcoholic fatty liver disease in combination with the syndrome of intestinal bacterial overgrowth. Сучасна гастроентерологія, 0(1), 77-84. https://europub.co.uk/articles/-A-508547